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a b s t r a c t
Thalidomide is an immunomodulatory and anti-inflammatory agent and is used in autoimmune disor-
ders. It has been shown that thalidomide inhibits proinflammatory cytokines production. The purpose
of this study was to investigate the effect of thalidomide on the prevention of autoimmune diabetes in
mice. Diabetes was induced by multiple low-dose of streptozotocin (MLDS) injection. Mice were treated
with thalidomide (300 mg/kg/day orally) for 21 days. Plasma levels of glucose, insulin and nitrate/nitrite
as well as pancreatic cytokine levels were measured. Pathological examinations of the pancreas revealed
that thalidomide reduced the islet inflammation (insulitis) and destruction of beta cells. Thalidomide
treatment prevented hyperglycemia and preserved pancreatic insulin secretion in the diabetic mice. Tha-
lidomide treatment also significantly decreased plasma levels of nitric oxide and pancreatic proinflam-
matory cytokines [tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, IL-12, IL-17 and interferon
(IFN)-c)] while increased anti-inflammatory cytokine IL-10. In conclusion, these findings indicate that
thalidomide may have a protective effect against the autoimmune destruction of the pancreatic beta-cells
during the development of MLDS-induced type 1 diabetes in mice.
Ó 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Type 1 diabetes is a T-cell mediated autoimmune disease char-
acterized by the selective destruction of insulin-producing b-cells
in the pancreatic islets of Langerhans. Chronic pancreatic inflam-
mation (insulitis) and destruction of islet b-cells in type 1 diabetes
is mediated by the immune cells, particularly autoreactive CD4 and
CD8 T lymphocytes, B-cells, macrophages and dendritic cells [1].
T-cells can directly destroy b-cells through a cytotoxic process,
and they can also destroy b-cells through the secretion of proin-
flammatory cytokines. Moreover, in response to cytokine stimula-
tion, b-cells generate reactive oxygen species (ROSs) and reactive
nitrogen species such as nitric oxide (NO), which facilitate their
destruction [2]. NO is also synthesized within cytokine-activated
macrophages by inducible nitric oxide synthase (iNOS) [3]. T help-
er 1 cells produce proinflammatory cytokines (TNF-a, IFN-c, IL-1b,
IL-6, IL-12) which activate macrophages and cytotoxic T cells to
destroy b-cells, whereas IL-4 and IL-10 cytokines that are produced
by activated T helper 2 cells, prevent b-cell destructive insulitis [4].
Experimental insulin-dependent diabetes can be induced by
multiple low doses of streptozotocin (STZ) (MLDS) in rodents [5].
MLDS is a commonly used animal model that has many histologi-
cal and clinical features similar to those of human type 1 diabetes
and involves the participation of macrophages and T cells. STZ is a
pancreatic b-cell toxin that induces inflammation of the islets by
immune cells when it is given in multiple low doses [6]. The MLDS
model has been used widely to study the immunological pathways
that lead to b-cell death and progressive hyperglycemia.
It has been shown that some drugs such as thalidomide have
immunomodulatory and anti-inflammatory activity, which might
represent a potential preventive therapy for autoimmune diseases.
Thalidomide (a-N-phthalimido glutarimide) is a glutamic acid
derivative that was first introduced in 1954 as a sedative drug
but was withdrawn from the market due to its teratogenic effects.
Thalidomide has various pharmacological properties and it has
been used successfully for various inflammatory and autoimmune
diseases. Thalidomide was approved by the FDA for the treatment
of erythema nodosum leprosum (ENL) and multiple myeloma [7].
It has also been demonstrated that thalidomide or its analogs are
effective in the treatment of rheumatoid arthritis, Crohn’s disease,
prostate cancer, Behcet’s disease, chronic host-versus-graft dis-
ease, lupus erythematosis and HIV-associated oral ulcers [8–11].
However, teratogenicity, peripheral neuropathy and other adverse
effects of thalidomide have led to the design of its new analogs.
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